Treatment and Maintenance Therapy in Advanced Ovarian Cancer

SGO 2022 Conference Coverage on VuMedi
M

SGO 2022 on a Phase 2 OVARIO Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Frontline PBC With Bevacizumab

By SGO 2022 Conference Coverage on VuMedi FEATURING Melissa Hardesty
By SGO 2022 Conference Coverage on VuMedi FEATURING Melissa Hardesty
289 views
April 1, 2022
Comments 0
Login to view comments. Click here to Login
13:44

Niraparib Therapy in Patients With Newly Diagnosed Advanced Ovarian …

Antonio González-Martín

227 views
16:30

2021 Updates on Gynecologic Oncology: Impact on Patients, Overview o…

University of Colorado Cancer Center

B. Bitler, S. Guntupalli, C. Walsh

335 views
11:38

Labeled Indications for PARPi Monotherapy & PARPi+ Bevacizumab: How …

Michael Birrer

347 views
22:23

PARPi in 1L Advanced Ovarian Cancer: PFS Data for Olaparib, Nirapari…

Angela George

378 views
24:01

Updates in Ovarian Cancer Management: Treatment Options and Molecula…

Total Health

M. Yatsko

213 views
17:50

Updates From the PRIMA Trial: Niraparib as 1L Maintenance in Advance…

Kenrick Ng

839 views
59:52

Targeting DNA Damage Response in Ovarian Cancer: Are PARPi Just the …

Nebraska Oncology Society

K. Moore

736 views
23:10

Targeted Therapy for Advanced Ovarian Cancer

Ramez Eskander

503 views
20:53

Advances in IO Maintenance Treatment of Ovarian Cancer

CECOG Academy

C. Grimm

380 views
23:01

PARPi in DNA Repair-Associated Cancers: Predictors of Benefit, Mecha…

UChicago Genetics in Clinical Cancer Care: From Family Reunions to the Frontline of Developmental Therapeutics

G. Fleming

289 views
11:37

Developments in Frontline Therapy in Ovarian Cancer

Jonathan Ledermann

382 views
05:33

PARPi Maintenance Therapy in Advanced Ovarian Cancer: A Brief Review

Catherine Watson

256 views
11:28

SGO 2022: Recognition and Management of Side Effects Associated With…

SGO 2022 Conference Coverage on VuMedi

M. Raza Mirza

133 views